D. van der Heijde
About
D. van der Heijde is a scholar working on Rheumatology, Immunology and Hematology.
According to data from OpenAlex, D. van der Heijde has authored 55 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Rheumatology, 22 papers in Immunology and 10 papers in Hematology. Recurrent topics in D. van der Heijde's work include Rheumatoid Arthritis Research and Therapies (40 papers), Spondyloarthritis Studies and Treatments (27 papers) and Psoriasis: Treatment and Pathogenesis (21 papers). D. van der Heijde is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (40 papers), Spondyloarthritis Studies and Treatments (27 papers) and Psoriasis: Treatment and Pathogenesis (21 papers). D. van der Heijde collaborates with scholars based in Netherlands, United States and Germany. D. van der Heijde's co-authors include S van der Linden, Maxime Dougados, R. B. M. Landewé, Ignazio Olivieri, Martín Rudwaleit, Joachim Sieper, J. Brandt, Filip Van den Bosch, Salvatore Scarpato and Euthalia Roussou and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Value in Health.
In The Last Decade
D. van der Heijde
51 papers receiving 2.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| D. van der Heijde Netherlands | 11 | 2.3k | 972 | 833 | 197 | 189 | 55 | 2.5k | ||
| Pascal Claudepierre France | 30 | 2.5k 1.1× | 1.4k 1.4× | 686 0.8× | 167 0.8× | 404 2.1× | 186 | 3.2k | ||
| Angela Padula Italy | 34 | 2.4k 1.1× | 859 0.9× | 607 0.7× | 144 0.7× | 184 1.0× | 127 | 3.0k | ||
| Adeline Ruyssen‐Witrand France | 24 | 1.5k 0.7× | 567 0.6× | 555 0.7× | 198 1.0× | 160 0.8× | 109 | 2.2k | ||
| Rafael Valle‐Oñate Colombia | 18 | 1.6k 0.7× | 799 0.8× | 592 0.7× | 247 1.3× | 128 0.7× | 59 | 1.9k | ||
| H. Kellner Germany | 15 | 1.9k 0.8× | 825 0.8× | 762 0.9× | 116 0.6× | 89 0.5× | 52 | 2.3k | ||
| Wayne Tsuji United States | 22 | 2.9k 1.3× | 1.4k 1.5× | 1.0k 1.2× | 576 2.9× | 479 2.5× | 26 | 3.7k | ||
| R. H. W. M. Derksen Netherlands | 25 | 1.3k 0.6× | 619 0.6× | 544 0.7× | 149 0.8× | 47 0.2× | 41 | 1.9k | ||
| Juan Mulero Spain | 23 | 1.2k 0.5× | 744 0.8× | 453 0.5× | 133 0.7× | 135 0.7× | 62 | 1.6k | ||
| D. van der Heijde Netherlands | 16 | 1.3k 0.6× | 492 0.5× | 415 0.5× | 65 0.3× | 93 0.5× | 72 | 1.6k | ||
| C. Stolwijk Netherlands | 17 | 1.7k 0.7× | 976 1.0× | 474 0.6× | 150 0.8× | 214 1.1× | 34 | 1.9k |
Countries citing papers authored by D. van der Heijde
Since
Specialization
Citations
This map shows the geographic impact of D. van der Heijde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. van der Heijde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. van der Heijde more than expected).
Fields of papers citing papers by D. van der Heijde
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by D. van der Heijde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. van der Heijde. The network helps show where D. van der Heijde may publish in the future.
Co-authorship network of co-authors of D. van der Heijde
This figure shows the co-authorship network connecting the top 25 collaborators of D. van der Heijde. A scholar is included among the top collaborators of D. van der Heijde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. van der Heijde. D. van der Heijde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Heijde, D. van der, Piotr Adrian Klimiuk, Guillermo J. Valenzuela, et al.. (2024). OP0138 EFFICACY AND SAFETY OUTCOMES OF TAK-279, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 83. 149–151.
2.
Heijde, D. van der, et al.. (2024). AB0403 INFLUENCE OF BODY WEIGHT, SEX AND PRIOR BIOLOGIC HISTORY ON TREATMENT OUTCOMES ASSOCIATED WITH TAK-279, A HIGHLY SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2B RANDOMIZED TRIAL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 83. 1449–1449.
3.
Mease, Philip J., Xenofon Baraliakos, Soumya D. Chakravarty, et al.. (2022). POS1037 EFFECT OF GUSELKUMAB, A SELECTIVE IL-23p19 INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PsA: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS. Annals of the Rheumatic Diseases. 81. 832–833.
4.
Braun, Jürgen, J. Sieper, Robert Landewé, et al.. (2017). Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies. Data Archiving and Networked Services (DANS). 69.
5.
Takeuchi, Tsutomu, Yoshiya Tanaka, Satoshi Soen, et al.. (2017). SAT0186 Effects of denosumab, a subcutaneous rankl inhibitor, on the progression of structural damage in japanese patients with rheumatoid arthritis treated with csdmards: results from the 12-month double blind phase 3, desirable study. Annals of the Rheumatic Diseases. 76. 841–842.
6.
Taylor, Peter C., E C Keystone, D. van der Heijde, et al.. (2015). Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study. Data Archiving and Networked Services (DANS). 67. 8–8.
7.
Haavardsholm, Espen A., Anna‐Birgitte Aga, Inge Christoffer Olsen, et al.. (2015). Aiming for Remission in Rheumatoid Arthritis : Clinical and Radiographic Outcomes from a Randomized Controlled Strategy Trial Investigating the Added Value of Ultrasonography in a Treat-to-Target Regimen. Data Archiving and Networked Services (DANS). 67.
8.
Steenbergen, H.W. van, Wouter Stomp, T. Stijnen, et al.. (2015). SAT0041 The Course of Bone Marrow Edema in Early Undifferentiated and Rheumatoid Arthritis; A Longitudinal MRI Study on Bone Level. Annals of the Rheumatic Diseases. 74. 663–663.
9.
Dougados, Maxime, D. van der Heijde, Yu‐Chi Chen, et al.. (2015). LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study. Annals of the Rheumatic Diseases. 74. 79–79.
10.
Maksymowych, Walter P., R. Landewé, Martín Rudwaleit, et al.. (2014). Effect of Certolizumab Pegol Over 48 Weeks in Patients with Axial Spondyloarthritis, including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. The Journal of Rheumatology. 41(7). 1496–1497.
11.
Essers, Ivette, S. Ramiro, C. Stolwijk, et al.. (2014). Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Lara D. Veeken. 54(4). 633–640.
12.
Keystone, E C, F. C. Breedveld, D. van der Heijde, et al.. (2013). Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By 2 Years in Patients With Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial. Data Archiving and Networked Services (DANS). 65.
13.
Wollenhaupt, J., D. Gladman, C. Stach, et al.. (2013). Effect Of Certolizumab Pegol Over 48 Weeks On Signs and Symptoms In Patients With Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Exposure. The Journal of Rheumatology. 41(7). 1448–1449.
14.
Keystone, Edward, D. van der Heijde, M. Weinblatt, et al.. (2011). Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial. Data Archiving and Networked Services (DANS). 63(10).
15.
Emery, Paul, D. van der Heijde, Mikkel Østergaard, et al.. (2011). Magnetic resonance imaging assessments of patients with RA and their association with clinical and radiographic outcomes. Annals of the Rheumatic Diseases. 70.
16.
Breedveld, F. C., Edward Keystone, D. van der Heijde, et al.. (2011). Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial. Data Archiving and Networked Services (DANS). 63(10). 118–119.
17.
Kavanaugh, Arthur, D. van der Heijde, D. Gladman, et al.. (2010). GOLIMUMAB INHIBITS PROGRESSION OF RADIOGRAPHIC DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM THE GO-REVEAL STUDY. Lara D. Veeken. 50. 143–143.
18.
Rudwaleit, Martín, D. van der Heijde, R. B. M. Landewé, et al.. (2010). The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Annals of the Rheumatic Diseases. 70(1). 25–31.
19.
Heijde, D. van der, et al.. (2010). SHOULD ACPA STATUS BE REASSESSED IN PATIENTS WITH EARLY ARTHRITIS: RESULTS FROM FOLLOW-UP EXAMINATIONS IN PATIENTS WITH ARTHRITIS OF LESS THAN 16 WEEKS DURATION. Scandinavian Journal of Rheumatology. 39. 22–22.
20.
Boonen, Annelies, D. van der Heijde, Robert Landewé, et al.. (2005). The SF-6D differentiates less in the lower ranges of the patient's utility when compared with the EQ-5D but has a better reliability and sensitivity to change. Annals of the Rheumatic Diseases. 64. 390–390.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Pascal Claudepierre Breakdown of academic impact, for papers by Angela Padula Breakdown of academic impact, for papers by Adeline Ruyssen‐Witrand Breakdown of academic impact, for papers by Rafael Valle‐Oñate Breakdown of academic impact, for papers by H. Kellner Breakdown of academic impact, for papers by Wayne Tsuji Breakdown of academic impact, for papers by R. H. W. M. Derksen Breakdown of academic impact, for papers by Juan Mulero Breakdown of academic impact, for papers by D. van der Heijde Breakdown of academic impact, for papers by C. Stolwijk